Tag: economic implications

Disparities in Weight Loss Prescriptions The disparity in access to medications like Wegovy, Rybelsus, and Ozempic highlights a significant issue within the U.S. healthcare system. Despite the increasing medical applications of these drugs, which include managing diabetes and potentially preventing heart disease and stroke, many insurers remain reluctant to cover them for weight loss. Medicare, for example, is legally barred from covering weight-loss drugs unless the patient presents serious health risks. This limitation leaves over two-fifths of American adults who are obese but otherwise healthy without coverage options. Federal spending…